艾滋病药物多替阿巴拉米片效果怎么样？

(Dolutegravir tablets) is currently the only three-in-one compound drug containing dolutegravir (DrG), which integrates treatment drugs for different stages of viral infection into the same tablet. Patients only need to take one drug to achieve the effect of combined medication. The drug has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection.

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. Comparing it with the other two integrase inhibitor first-line regimens of RAL (Ascent) and EVG (elvitegravir) in patients who failed treatment, Suimeike (Dolutea Balamib Tablets) has significantly fewer drug-resistant mutation sites than the other two drugs, making it less likely to develop drug resistance. Suimeikai (dolute abalamib tablets) has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients.

In the real world, antiviral treatment-naïve patients treated with DTG have a lower proportion of central nervous system-related (CNS) adverse events than the four drugs RAL (Ascent), DRV/r (darunavir), EFV (efavirenz) and ATV/r (atazanavir). Therefore, the DTG integrase inhibitor as the core (dolute abalamib tablets) is controllable and effective in terms of drug safety and effectiveness.